Synthetic Biology Medicine and Bacteria-Based Cancer Therapeutics
| Autor: | Jaehyung, Lee, Andrew C, Keates, Chiang J, Li |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Salmonella typhimurium
Mice Inbred BALB C Clinical Trials Phase I as Topic Genetic Vectors Remission Induction Mice Nude Real-Time Polymerase Chain Reaction Xenograft Model Antitumor Assays Specific Pathogen-Free Organisms Biological Therapy Mice Inbred C57BL Mice Species Specificity Cell Line Tumor Neoplasms Colonic Neoplasms Escherichia coli Animals Humans Female RNA Interference Synthetic Biology Immunotherapy RNA Messenger RNA Small Interfering |
| Zdroj: | Methods in molecular biology (Clifton, N.J.). 2323 |
| ISSN: | 1940-6029 |
| Popis: | Spontaneous tumor regression following bacterial infection has been observed for hundreds of years. These observations along with anecdotal medical findings in 1890s led to the development of Coley's "toxins," consisting of killed Streptococcus pyogenes and Serratia marcescens bacteria, as the first cancer immunotherapy. The use of this approach, however, was not widely accepted at the time especially after the introduction of radiation therapy as a treatment for cancer in the early 1900s. Over the last 30-40 years there has been renewed interest in the use of bacteria to treat human solid tumors. This is based on the observation that various nonpathogenic anaerobic bacteria can infiltrate and replicate within solid tumors when given intravenously. Bacteria tested as potential anticancer agents include the Gram-positive obligate anaerobes Bifidobacterium and Clostridium, as well as the gram-negative facultative anaerobe Salmonella. Recent advances in synthetic biology and clinical success in cancer immunotherapy provide renewed momentum for developing bacteria-based cancer immunotherapy for cancer treatment and should allow greater potential for the development of novel therapeutic approaches for this devastating disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|